GLORIA

GEOMAR Library Ocean Research Information Access

X

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
  • Wiley  (4)
  • Ohyama, Chikara  (4)
  • 1
    Online-Ressource
    Online-Ressource
    Characteristics of α2,3‐sialyl N ‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level
    Wiley ; 2021
    In:  The Prostate Vol. 81, No. 16 ( 2021-12), p. 1411-1427
    Details
    In: The Prostate, Wiley, Vol. 81, No. 16 ( 2021-12), p. 1411-1427
    Kurzfassung: The presence of glycosylated isoforms of prostate‐specific antigen (PSA) in prostate cancer (PC) cells is a potential marker of their aggressiveness. We characterized the origin of α2,3‐sialylated prostate‐specific antigen (S23PSA) by tissue‐based sialylation‐related gene expression and studied the performance of S23PSA density (S23PSAD) alone and in combination with multiparametric magnetic resonance imaging (MRI) for the detection of clinically significant prostate cancer in men with elevated PSA. Methods Tissue‐based quantification of S23PSA and sialyltransferase and sialidase gene expression was evaluated in 71 radical prostatectomy specimens. The diagnostic performance of S23PSAD was studied in 1099 men retrospectively enrolled in a multicenter systematic biopsy (SBx) cohort. We correlated the S23PSAD with Prostate Imaging Reporting and Data System (PI‐RADS) scores in 98 men prospectively enrolled in a single‐center MRI‐targeted biopsy (MRI–TBx) cohort. The primary outcome was the PC‐diagnostic performance of the S23PSAD, the secondary outcome was the avoidable biopsy rate of S23PSAD combined with DRE and total PSA (tPSA), and with or without PI‐RADS. Results S23PSA was significantly higher in Gleason pattern 4 and 5 compared with benign prostate tissue. In the retrospective cohort, the performance of S23PSAD for detecting PC was superior to tPSA or PSA density (PSAD) (AUC: 0.7758 vs. 0.6360 and 0.7509, respectively). In the prospective cohort, S23PSAD was superior to tPSA, PSAD, and PI‐RADS (AUC: 0.7725 vs. 0.5901, 0.7439 and 0.7305, respectively), and S23PSAD + PI‐RADS + DRE + tPSA was superior to DRE + tPSA+PI‐RADS with avoidance rate of MRI–TBx (13% vs. 1%) at 30% risk threshold. Conclusions The diagnostic performance of S23PSAD was superior to conventional strategies but comparable to mpMRI.
    Materialart: Online-Ressource
    ISSN: 0270-4137 , 1097-0045
    URL: Issue
    URL: Article
    DOI: 10.1002/pros.v81.16
    DOI: 10.1002/pros.24239
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2021
    ZDB Id: 1494709-2
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Online-Ressource
  • 2
    Online-Ressource
    Online-Ressource
    Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer
    Wiley ; 2022
    In:  BJUI Compass Vol. 3, No. 2 ( 2022-03), p. 146-153
    Details
    In: BJUI Compass, Wiley, Vol. 3, No. 2 ( 2022-03), p. 146-153
    Kurzfassung: To evaluate the effect of postoperative pathological findings related to the eligibility of adjuvant immunotherapy on oncologic outcomes in patients with localized and locally advanced muscle‐invasive bladder carcinoma (MIBC) and upper tract urothelial carcinoma (UTUC). Patients and methods We retrospectively evaluated 1082 patients treated with radical cystectomy ( n  = 597) and nephroureterectomy ( n  = 485) between January 2000 and April 2021. Patients were divided into two groups: pT3‐4 or pN+ without neoadjuvant chemotherapy and ypT2‐4 or pN+ treated with neoadjuvant chemotherapy (trial‐eligible group) or others (trial‐ineligible group). The primary outcome was the effect of trial eligibility for adjuvant immunotherapy on disease‐free survival (DFS) and overall survival (OS). Secondary outcomes included the additional effect of lymphovascular invasion (LVI) status to the clinical trial criteria on prognosis and a risk model development. Results The median ages of the patients were 69 and 72 years in the MIBC and UTUC groups, respectively. Fifty‐two percent of patients met the trial inclusion criteria. Trial eligibility was significantly associated with poor DFS and OS among patients with MIBC and UTUC. LVI‐positive status was significantly associated with poor prognosis among patients in the trial‐eligible group. A very high risk (LVI+ or pN+ among the pT3‐4 or ypT2‐4) was significantly associated with poor prognosis. Conclusion A total of 52% of patients were eligible for adjuvant immunotherapy. Trial eligibility was significantly associated with a poor prognosis. LVI+ and pN+ may play a key role in candidate selection for adjuvant immunotherapy.
    Materialart: Online-Ressource
    ISSN: 2688-4526 , 2688-4526
    URL: Issue
    URL: Article
    DOI: 10.1002/bco2.v3.2
    DOI: 10.1002/bco2.117
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2022
    ZDB Id: 3015455-8
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Online-Ressource
  • 3
    Online-Ressource
    Online-Ressource
    Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high‐risk non‐muscle‐invasive bladder cancer who receive adjuvant induction bacillus Calmette‐Guérin therapy
    Wiley ; 2022
    In:  International Journal of Urology Vol. 29, No. 8 ( 2022-08), p. 867-875
    Details
    In: International Journal of Urology, Wiley, Vol. 29, No. 8 ( 2022-08), p. 867-875
    Kurzfassung: To investigate whether a single intravesical instillation of chemotherapy is associated with improved oncological outcomes in patients with high‐risk non‐muscle‐invasive bladder cancer who receive adjuvant induction bacillus Calmette‐Guérin therapy. Methods This multi‐institutional retrospective study included 205 patients with high‐risk non‐muscle‐invasive bladder cancer who received adjuvant induction bacillus Calmette‐Guérin therapy. Patients were divided into two groups: those who received the combined therapy of a single instillation of chemotherapy plus subsequent adjuvant induction bacillus Calmette‐Guérin therapy (combined therapy group), and those who received adjuvant induction bacillus Calmette‐Guérin therapy alone (bacillus Calmette‐Guérin monotherapy group). Multivariable analyses using the inverse probability of treatment weighting method and Fine‐Gray competing risk regression models were performed to evaluate the impact of a single instillation of chemotherapy on intravesical recurrence‐free survival and muscle‐invasive bladder cancer‐free survival. Results Among the 205 patients, 130 (63%) and 75 (37%) were classified as the combined therapy and bacillus Calmette‐Guérin monotherapy groups, respectively. Multivariable analyses using the inverse probability of treatment weighting method showed that a single instillation of chemotherapy was significantly associated with longer intravesical recurrence‐free survival (hazard ratio 0.279; P   〈  0.001) and muscle‐invasive bladder cancer‐free survival (hazard ratio 0.078; P   〈  0.001). Fine‐Gray competing risk regression model revealed that a single instillation of chemotherapy was associated with a significantly lower probability of intravesical recurrence and muscle‐invasive bladder cancer progression, with an adjusted subdistribution hazard ratio of 0.477 ( P  = 0.008) and 0.261 ( P  = 0.043), respectively. Conclusion A single intravesical instillation of chemotherapy may be a potential treatment option in patients with high‐risk non‐muscle‐invasive bladder cancer who receive adjuvant induction bacillus Calmette‐Guérin therapy.
    Materialart: Online-Ressource
    ISSN: 0919-8172 , 1442-2042
    URL: Issue
    URL: Article
    DOI: 10.1111/iju.v29.8
    DOI: 10.1111/iju.14926
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2022
    ZDB Id: 2009793-1
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Online-Ressource
  • 4
    Online-Ressource
    Online-Ressource
    Efficacy and safety of first‐line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study
    Wiley ; 2020
    In:  International Journal of Urology Vol. 27, No. 12 ( 2020-12), p. 1095-1100
    Details
    In: International Journal of Urology, Wiley, Vol. 27, No. 12 ( 2020-12), p. 1095-1100
    Kurzfassung: To investigate the efficacy and safety of first‐line nivolumab plus ipilimumab for patients treated with metastatic renal cell carcinoma. Methods We retrospectively evaluated 52 metastatic renal cell carcinoma patients who were treated with nivolumab plus ipilimumab between August 2015 and January 2020. Data on patient characteristics, treatment parameters and adverse events were obtained. Oncological outcomes were assessed according to the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model. Furthermore, differences in treatment parameters between patients with objective response (responders) and non‐responders were compared. Results The median age and follow‐up periods were 69 years and 8.2 months, respectively. The 1‐year progression‐free survival and overall survival rates were 55% and 75%, respectively. The objective response rate was 39%, and it was significantly different between the International Metastatic Renal Cell Carcinoma Database Consortium intermediate‐ and poor‐risk groups (52% vs 24%). We observed 36 (69%) any immune‐related adverse events, and 19 (37%) severe immune‐related adverse events (grades III–V). The International Metastatic Renal Cell Carcinoma Database Consortium poor‐risk group and higher value of initial C‐reactive protein (≥1.0 mg/dL) were significantly associated with non‐responders. Patients with two factors (the International Metastatic Renal Cell Carcinoma Database Consortium poor‐risk group plus C‐reactive protein ≥1.0 mg/dL) had a significantly poor overall survival than those with none or a single factor. Conclusions In our experience, treatment response to nivolumab plus ipilimumab is comparable with that of the CheckMate 214 clinical trial, but the incidence of treatment‐related adverse events is lower. The International Metastatic Renal Cell Carcinoma Database Consortium poor‐risk group and initial C‐reactive protein value might have a prognostic value for poor survival.
    Materialart: Online-Ressource
    ISSN: 0919-8172 , 1442-2042
    URL: Issue
    URL: Article
    DOI: 10.1111/iju.v27.12
    DOI: 10.1111/iju.14363
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2020
    ZDB Id: 2009793-1
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Online-Ressource
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...